Extracorporeal elimination of circulating pegylated liposomal doxorubicin (PLD) to enhance the benefit of cytostatic therapy in platinum-resistant ovarian cancer patients

Title:

Extracorporeal elimination of circulating pegylated liposomal doxorubicin (PLD) to enhance the benefit of cytostatic therapy in platinum-resistant ovarian cancer patients
Extracorporeal elimination of circulating pegylated liposomal doxorubicin (PLD) to enhance the benefit of cytostatic therapy in platinum-resistant ovarian cancer patients

Creator:

Kubeček, Ondřej, Bláha, Milan, Diaz-Garcia, Daniel, and Filip, Stanislav

Contributor:

Kubeček, Ondřej, Bláha, Milan , 1938-, Diaz-Garcia, Daniel, and Filip, Stanislav , 1961-

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:bmc15040796-50a9f00f-5e6d-46de-8b7f-4139459a3ad8
uuid:bmc15040796-50a9f00f-5e6d-46de-8b7f-4139459a3ad8
local:bmc15040796
http://actamedica.lfhk.cuni.cz/
doi: 10.14712/18059694.2015.84
local: bmc15040796

Subject:

antibiotika antitumorózní--krev--terapeutické užití, cytostatické látky, doxorubicin--analogy a deriváty--krev--terapeutické užití, chemorezistence, mimotělní oběh, ženské pohlaví, lidé, nádory vaječníků--krev--farmakoterapie, sloučeniny platiny--terapeutické užití, and polyethylenglykoly--terapeutické užití

Type:

model:article, article, Text, časopisecké články, práce podpořená grantem, přehledy, and TEXT

Format:

print, text, and regular print

Description:

Ovarian cancer is the fifth most common malignancy in the world's female population and with the highest lethality index among gynecological tumors. The prognosis of metastatic disease is usually poor, especially in platinum-resistant cases. There are several options for the treatment of metastatic disease resistant to platinum derivates (e.g. paclitaxel, topotecan and pegylated liposomal doxorubicin), all of which are considered equipotent. Pegylated liposomal doxorubicin (PLD) is a liposomal form of the anthracycline antibiotic doxorubicin. It is characterized by more convenient pharmacokinetics and a different toxicity profile. Cardiotoxicity, the major adverse effect of conventional doxorubicin, is reduced in PLD as well as hematotoxicity, alopecia, nausea and vomiting. Skin toxicity and mucositis, however, emerge as serious issues since they represent dose and schedule-limiting toxicities. The pharmacokinetics of PLD (prolonged biological half-life and preferential distribution into tumor tissue) provide new possibilities to address these toxicity issues. The extracorporeal elimination of circulating liposomes after PLD saturation in the tumor tissue represents a novel and potent strategy to diminish drug toxicity. This article intends to review PLD characteristics and the importance of extracorporeal elimination to enhance treatment tolerance and benefits. and O. Kubeček, M. Bláha, D. Diaz-Garcia, S. Filip

Language:

English

Rights:

http://creativecommons.org/publicdomain/mark/1.0/
policy:public

Relation:

Acta medica (Hradec Králové) Universitas Carolina, Facultas Medica Hradec Králové--MED00010947

Source:

Acta medica (Hradec Králové) | 2015 Volume:58 | Number:1

Harvested from:

CDK

Metadata only:

false

Date:

2015